Takeda Announces FDA Acceptance Of BLA For Subcutaneous Administration Of ENTYVIO For Maintenance Therapy In Moderately To Severely Active Crohn's Disease
Portfolio Pulse from Bill Haddad
The FDA has accepted Takeda's Biologics License Application (BLA) for the subcutaneous administration of ENTYVIO, a maintenance therapy for moderately to severely active Crohn's disease.
September 13, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Takeda's BLA for ENTYVIO has been accepted by the FDA, potentially leading to a new treatment option for Crohn's disease.
The FDA's acceptance of Takeda's BLA for ENTYVIO is a positive development for the company. If approved, it could provide a new treatment option for Crohn's disease, potentially increasing Takeda's market share and revenues in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100